PubRank

A Gatta

Author PubWeight™ 114.27‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Long term effect of alpha interferon in children with chronic hepatitis B. Gut 2000 2.21
2 Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive emergencies. A randomized, single-blind clinical trial. Arch Intern Med 1991 1.91
3 Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999 1.74
4 Renal vasoconstriction in cirrhosis evaluated by duplex Doppler ultrasonography. Hepatology 1993 1.69
5 Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial. Gut 2010 1.65
6 Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 1994 1.65
7 Nutrition and survival in patients with liver cirrhosis. Nutrition 2001 1.60
8 Nutritional and prognostic significance of insulin-like growth factor 1 in patients with liver cirrhosis. Nutrition 1997 1.54
9 Spontaneous regression of hepatitis B virus-associated cirrhosis developed in childhood. Dig Liver Dis 2005 1.51
10 Splenic Doppler impedance indices: influence of different portal hemodynamic conditions. Hepatology 1996 1.46
11 Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV. Neurology 2006 1.42
12 Updating prognosis of cirrhosis by Cox's regression model using Child-Pugh score and aminopyrine breath test as time-dependent covariates. Ital J Gastroenterol Hepatol 1998 1.39
13 Hypophosphatemia and renal tubular dysfunction in alcoholics. Are they related to liver function impairment? Gastroenterology 1991 1.39
14 Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology 1999 1.25
15 Left ventricular diastolic function in liver cirrhosis. Scand J Gastroenterol 1996 1.25
16 The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000 1.24
17 Natural history of portal hypertensive gastropathy in patients with liver cirrhosis. The New Italian Endoscopic Club for the study and treatment of esophageal varices (NIEC). Gastroenterology 2000 1.24
18 Role of spleen enlargement in cirrhosis with portal hypertension. Dig Liver Dis 2002 1.18
19 Malnutrition in alcoholic and virus-related cirrhosis. Am J Clin Nutr 1996 1.16
20 Overexpression of squamous cell carcinoma antigen variants in hepatocellular carcinoma. Br J Cancer 2004 1.14
21 Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000 1.13
22 Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices. Gastroenterology 1992 1.10
23 Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. J Hepatol 2001 1.10
24 Spectral versus visual EEG analysis in mild hepatic encephalopathy. Clin Neurophysiol 1999 1.08
25 Clinical significance of the evaluation of hepatic reticuloendothelial removal capacity in patients with cirrhosis. Hepatology 1994 1.07
26 Two PKR inhibitor HCV proteins correlate with early but not sustained response to interferon. Gastroenterology 2000 1.05
27 The course of galactose elimination capacity in patients with alcoholic cirrhosis: possible use as a surrogate marker for death. Hepatology 1996 1.04
28 Prognostic value of galactose elimination capacity, aminopyrine breath test, and ICG clearance in patients with cirrhosis. Comparison with the Pugh score. Dig Dis Sci 1991 1.04
29 Paraumbilical vein patency in cirrhosis: effects on hepatic hemodynamics evaluated by Doppler sonography. Hepatology 1995 1.03
30 Prognostic indicators of risk for first variceal bleeding in cirrhosis: a multicenter study in 711 patients to validate and improve the North Italian Endoscopic Club (NIEC) index. Am J Gastroenterol 2000 1.01
31 Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut 2001 1.01
32 Eicosanoid excretion in hepatic cirrhosis. Predominance of 20-HETE. J Clin Invest 1997 1.00
33 Insulin-like growth factor 1 (IGF-1), a nutritional marker in patients with eating disorders. Clin Nutr 2001 0.99
34 Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology 1998 0.99
35 Noninvasive grading of the severity of portal hypertension in cirrhotic patients by echo-color-Doppler. Ultrasound Med Biol 2001 0.98
36 Evaluation of a new endoscopic index to predict first bleeding from the upper gastrointestinal tract in patients with cirrhosis. Hepatology 1996 0.95
37 Hepatic arterial resistance in cirrhosis with and without portal vein thrombosis: relationships with portal hemodynamics. Gastroenterology 1995 0.93
38 Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group. Hepatogastroenterology 2000 0.92
39 Improvement of liver cancer detection with simultaneous assessment of circulating levels of free alpha-fetoprotein (AFP) and AFP-IgM complexes. Int J Biol Markers 2004 0.92
40 Doppler sonography and hepatic vein catheterization in portal hypertension: assessment of agreement in evaluating severity and response to treatment. J Hepatol 1998 0.91
41 Aminopyrine breath test in the prognostic evaluation of patients with cirrhosis. Gut 1992 0.90
42 Diagnostic tools for the detection of subclinical hepatic encephalopathy: comparison of standard and computerized psychometric tests with spectral-EEG. Metab Brain Dis 1996 0.90
43 Neurological complications after orthotopic liver transplantation. Dig Liver Dis 2007 0.89
44 Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Aliment Pharmacol Ther 2006 0.89
45 Effect of nadolol on liver haemodynamics and function in patients with cirrhosis. Br J Clin Pharmacol 1986 0.88
46 Effect of somatostatin on splanchnic hemodynamics in patients with liver cirrhosis and portal hypertension. Digestion 1985 0.88
47 Thrombosis of the portal venous system. J Ultrasound 2007 0.87
48 Long-term follow-up study of adult patients with non-cirrhotic obstruction of the portal system: comparison with cirrhotic patients. J Hepatol 1992 0.87
49 Cirrhosis and muscle cramps: evidence of a causal relationship. Hepatology 1996 0.86
50 Splenic haemodynamics and portal hypertension in patients with liver cirrhosis and spleen enlargement. Clin Physiol 1985 0.86
51 Q-T interval prolongation in liver cirrhosis. Reversibility after orthotopic liver transplantation. Jpn Heart J 1998 0.86
52 Study on the Sternberg paradigm in cirrhotic patients without overt hepatic encephalopathy. Metab Brain Dis 1998 0.86
53 Neurocognitive-neurological complications of liver transplantation: a review. Metab Brain Dis 2010 0.85
54 Arterioportal fistulas in patients with liver cirrhosis: usefulness of color Doppler US for screening. Radiology 2000 0.84
55 Visual attention in cirrhotic patients: a study on covert visual attention orienting. Hepatology 1998 0.84
56 Renal water and sodium handling in compensated liver cirrhosis: mechanism of the impaired natriuresis after saline loading. Eur J Clin Invest 1985 0.84
57 The EEG assessment of low-grade hepatic encephalopathy: comparison of an artificial neural network-expert system (ANNES) based evaluation with visual EEG readings and EEG spectral analysis. Clin Neurophysiol 2006 0.83
58 Value of prealbumin plasma levels as liver test. Digestion 1987 0.83
59 Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP) Lancet 1997 0.83
60 Effect of somatostatin on liver blood flow and liver metabolic activity in patients with cirrhosis. Scand J Clin Lab Invest 1987 0.83
61 Prognostic indicators of survival in patients with cirrhosis and esophageal varices, without previous bleeding. Am J Gastroenterol 1989 0.83
62 Effects of isosorbide dinitrate on portal hypertension in alcoholic cirrhosis. J Hepatol 1987 0.83
63 Nadolol for prevention of variceal rebleeding in cirrhosis: a controlled clinical trial. Digestion 1987 0.82
64 Natural history of cirrhotic patients with small esophageal varices: a prospective study. Am J Gastroenterol 2000 0.82
65 Haeme oxygenase mediates hyporeactivity to phenylephrine in the mesenteric vessels of cirrhotic rats with ascites. Gut 2005 0.82
66 Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta-blocker alone. Hepatology 1997 0.81
67 Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma. Eur J Clin Invest 2008 0.81
68 Indocyanine green intrinsic hepatic clearance as a prognostic index of survival in patients with cirrhosis. J Hepatol 1989 0.81
69 Analysis of EEG tracings in frequency and time domain in hepatic encephalopathy. Comput Methods Programs Biomed 2006 0.81
70 Effect of chronic treatment with nadolol plus isosorbide mononitrate on liver blood flow and liver metabolic activity in cirrhosis. Eur J Gastroenterol Hepatol 1999 0.80
71 Portal hypertension and portal hypertensive gastropathy in patients with liver cirrhosis: a haemodynamic study. Dig Liver Dis 2003 0.80
72 Enhanced renal sympathetic tone in liver cirrhosis: evaluation by intrarenal administration of dihydroergocristine. Nephron 1982 0.80
73 Effect of triglycyl-lysin-vasopressin on quantitative liver function tests in patients with cirrhosis. Am J Gastroenterol 1992 0.80
74 The use of human albumin millimicrospheres tagged with 99mTc in the evaluation of the removal capacity of the reticuloendothelial system. Eur J Nucl Med 1987 0.80
75 Vegetarian diets in hepatic encephalopathy: facts or fantasies? Dig Liver Dis 2001 0.80
76 A patients' and caregivers' perspective on hepatic encephalopathy. Metab Brain Dis 2012 0.79
77 Increased activity of guanosine 3'-5'-cyclic monophosphate phosphodiesterase in the renal tissue of cirrhotic rats with ascites. Hepatology 2000 0.79
78 Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology 1994 0.79
79 Prognostic significance of portal hemodynamics in patients with compensated cirrhosis. J Hepatol 1993 0.79
80 Electroencephalographic analysis for the assessment of hepatic encephalopathy: comparison of non-parametric and parametric spectral estimation techniques. Neurophysiol Clin 2009 0.79
81 Neuropsychological-neurophysiological alterations and brain atrophy in cirrhotic patients. Metab Brain Dis 2003 0.79
82 Effects of nadolol treatment on renal and hepatic hemodynamics and function in cirrhotic patients with portal hypertension. Am Heart J 1984 0.79
83 Surface expression of squamous cell carcinoma antigen (SCCA) can be increased by the preS1(21-47) sequence of hepatitis B virus. J Gen Virol 2004 0.79
84 Blood flow of experimental liver metastases in rat as evaluated by the locally injected 133-Xenon washout. Res Exp Med (Berl) 1985 0.79
85 Carbohydrate and lipid metabolism in cirrhosis. Evidence that hepatic uptake of gluconeogenic precursors and of free fatty acids depends on effective hepatic flow. J Clin Endocrinol Metab 1984 0.79
86 Plasma carnitine levels in liver cirrhosis: relationship with nutritional status and liver damage. J Clin Chem Clin Biochem 1990 0.79
87 Ammonia-related changes in cerebral electrogenesis in healthy subjects and patients with cirrhosis. Clin Neurophysiol 2012 0.78
88 Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease. Dig Liver Dis 2008 0.78
89 Insulin-like growth factor 1 (IGF-1) in liver cirrhosis: a marker of hepatocellular dysfunction? J Hepatol 1998 0.78
90 Sleep and circadian rhythms in hospitalized patients with decompensated cirrhosis: effect of light therapy. Neurochem Res 2014 0.78
91 Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis. J Viral Hepat 2008 0.78
92 The calcium-channel blocker, verapamil, does not improve portal pressure in patients with alcoholic cirrhosis. Br J Clin Pharmacol 1988 0.78
93 Relationship between plasma levels of factor VIII related antigen and reticulo-endothelial function in chronic uremia. Clin Nephrol 1983 0.78
94 Effects of chronic therapy with nadolol on portal hemodynamics and on splanchnic impedance indices using Doppler sonography: comparison between acute and chronic effects. J Hepatol 1997 0.78
95 Renal and intrarenal blood flow in patients with cirrhosis before and after portal-systemic shunt. Scand J Gastroenterol 1980 0.78
96 P300 latency for the diagnosis of minimal hepatic encephalopathy: evidence that spectral EEG analysis and psychometric tests are enough. Dig Liver Dis 2005 0.78
97 Nutritional and prognostic significance of serum hypothyroxinemia in hospitalized patients with liver cirrhosis. J Hepatol 1998 0.78
98 Effects of iloprost, a prostacyclin analog derivative, on renal plasma flow, renal function, and renin-aldosterone system in humans. Clin Pharmacol Ther 1988 0.78
99 Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance. Eur J Clin Invest 1990 0.78
100 High levels of soluble tumor necrosis factor superfamily receptors in patients with hepatitis C virus infection and lymphoproliferative disorders. J Hepatol 2001 0.78
101 Reference ranges and methodological aspects in the urinary measuring of lysozyme, malate-dehydrogenase, gamma-glutamyltransferase and alpha-glucosidase. Enzyme 1985 0.78
102 Importance of the 1-month-effect of nadolol on portal pressure in predicting failure of prevention of rebleeding in cirrhosis. J Hepatol 1991 0.78
103 Proteinuria in patients with cirrhosis: relationship between renal and hepatic function. Clin Sci (Lond) 1982 0.78
104 Electroencephalographic staging of hepatic encephalopathy by an artificial neural network and an expert system. Neurophysiol Clin 2006 0.77
105 Visual attention orienting in liver cirrhosis without overt hepatic encephalopathy. Metab Brain Dis 1995 0.77
106 Duplex Doppler sonographic evaluation of splanchnic and renal effects of single agent and combined therapy with nadolol and isosorbide-5-mononitrate in cirrhotic patients. J Ultrasound Med 1994 0.77
107 Redistribution of renal blood flow in patients with liver cirrhosis. The role of renal PGE2. J Hepatol 1986 0.77
108 Long-term effect of nadolol or nadolol plus isosorbide-5-mononitrate on renal function and ascites formation in patients with cirrhosis. GTIP Gruppo Triveneto per l'Ipertensione Portale. Hepatology 1995 0.77
109 Renal cytochrome P-450-dependent metabolism of arachidonic acid in cirrhotic rats. J Hepatol 1991 0.77
110 Renal effects of aminophylline in hepatic cirrhosis. Eur J Clin Pharmacol 1983 0.77
111 Cardiac involvement in progressive systemic sclerosis. Acta Cardiol 1979 0.77
112 Can we predict the first variceal bleeding in the individual patient with cirrhosis and esophageal varices? J Hepatol 1991 0.76
113 Circadian variation in the frequency of acute variceal bleeding in cirrhosis. Gruppo Triveneto per l'Ipertensione Portale. J Hepatol 1994 0.76
114 Does defective chloride reabsorption at the loop of Henle play a major role in the pathogenesis of Bartter's syndrome? Am J Nephrol 1987 0.76
115 Lack of effect of verapamil and isosorbide dinitrate on the hepatic clearance of indocyanine green in cirrhosis. Br J Clin Pharmacol 1990 0.76
116 Juxtaglomerular cell tumor of the kidney. Clin Exp Hypertens 1994 0.76
117 Evaluation of the efficacy and safety of flumazenil in the treatment of portal systemic encephalopathy: a double blind, randomised, placebo controlled multicentre study. Gut 1996 0.76
118 Intrarenal blood flow, circulation time, and cortical vascular volume in patients with cirrhosis. Scand J Gastroenterol 1981 0.76
119 Pathogenetic relationships between renal tubular acidosis and sodium metabolism alterations in liver cirrhosis. Digestion 1983 0.75
120 Variability of atrial natriuretic peptide plasma levels in ascitic cirrhotics: pathophysiological and clinical implications. Hepatology 1992 0.75
121 Short-term effects of transcatheter arterial chemoembolisation on metabolic activity of the liver of cirrhotic patients with hepatocellular carcinoma. Gut 1996 0.75
122 Statistical methods for predicting variceal hemorrhage. Gastroenterology 1992 0.75
123 [Zinc deficiency in liver cirrhosis: a curiosity or a problem?]. Ann Ital Med Int 1998 0.75
124 Endotoxins and the hepatorenal syndrome. Lancet 1981 0.75
125 Pharmacokinetics of iloprost in patients with hepatic dysfunction. Int J Clin Pharmacol Ther Toxicol 1990 0.75
126 Use of a nonselective beta-blocker, nadolol, in the treatment of portal hypertension in cirrhotics. Int J Clin Pharmacol Res 1985 0.75
127 [Comparison of 2 indices of proximal tubular function. Malate dehydrogenase and beta-2-microglobulin]. Minerva Nefrol 1981 0.75
128 Renal haemodynamic in essential hypertension assessed by 133-Xenon washout and selective renal angiography. Angiology 1982 0.75
129 Intensive care complications in liver and multivisceral transplantation. Transplant Proc 2005 0.75
130 Verapamil pharmacokinetics and liver function in patients with cirrhosis. Int J Clin Pharmacol Res 1988 0.75
131 Effect of 8-day therapy with propionyl-L-carnitine on muscular and subcutaneous blood flow of the lower limbs in patients with peripheral arterial disease. Clin Physiol 1995 0.75
132 Effects of captopril on renal function in hypertensive patients. Am J Cardiol 1982 0.75
133 D-sorbitol clearance. Dig Dis Sci 1988 0.75
134 [Relationships between separated renin and renal and intrarenal flow (washout of Xe 133) in essential and secondary hypertension]. Boll Soc Ital Cardiol 1978 0.75
135 [Renal tubular damage in the initial phase of essential arterial hypertension]. Minerva Nefrol 1981 0.75
136 [Renal and intrarenal blood flow in essential arterial hypertension]. Minerva Nefrol 1981 0.75
137 ANP and PRA system response to phlebotomy. Am Heart J 1990 0.75
138 [Functional nephropathy in the course of hepatic cirrhosis. Pathogenetic relationships with changes in hepatic blood flow]. Minerva Nefrol 1979 0.75
139 Evaluation of splanchnic angiography as a prognostic index of survival in patients with cirrhosis. Scand J Gastroenterol 1991 0.75
140 Long-term effect of nadolol on quantitative liver function tests in patients with cirrhosis. Eur J Clin Pharmacol 1988 0.75
141 [The effectiveness of human albumin in liver failure]. Minerva Anestesiol 2005 0.75
142 The effect of flumazenil on subclinical psychometric or neurophysiological alterations in cirrhotic patients: a double-blind placebo-controlled study. Clin Physiol 1997 0.75
143 Are urinary enzymes useful markers of kidney damage in obstructive jaundice? An experimental study on Sprague-Dawley rats. Nephron 1985 0.75
144 Are prealbumin plasma levels linked to amino acid supply from peripheral tissues in liver cirrhosis? Amino Acids 1992 0.75
145 Beta 2-microglobulin concentration in plasma and production in liver cirrhosis. J Clin Chem Clin Biochem 1984 0.75
146 [Effect of somatostatin on splanchnic hemodynamics in liver cirrhosis]. Minerva Med 1984 0.75
147 Alcohol- and substance-dependent subjects: the correlated factors in qualifying for liver transplantation. Transplant Proc 2007 0.75
148 Comparison between nifedipine and carvedilol in the treatment of de novo arterial hypertension after liver transplantation: preliminary results of a controlled clinical trial. Transplant Proc 2005 0.75
149 The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group. J Hepatol 2000 0.75
150 Hypotensive and renal effects of captopril. Eur J Clin Invest 1981 0.75
151 Comparison of thrice weekly vs daily human leucocyte interferon-alpha therapy for chronic hepatitis C. TVVH Study Group. J Viral Hepat 1999 0.75
152 [Decrease in medio-renal and cortical renal blood flow in liver cirrhosis. Relationships with changes in systemic hemodynamics]. Minerva Nefrol 1979 0.75
153 Theophylline pharmacokinetics and liver function indexes in chronic liver disease. Respiration 1991 0.75
154 [Incomplete distal renal tubular acidosis in liver cirrhosis. A pathogenetic relation to renal and intrarenal hemodynamic changes]. Minerva Nefrol 1981 0.75
155 [Splenic hemodynamics and portal hypertension in splenomegalic hepatic cirrhosis]. G Clin Med 1983 0.75
156 [Physiopathology of nephropathy in liver cirrhosis. Pathogenetic role of ascites and of inferior vena cava pressure increase]. Minerva Dietol Gastroenterol 1979 0.75
157 Pre- and postoperative evaluation of vascular resistance in living related renal allografts under cyclosporine infusion. Transplant Proc 1994 0.75
158 Optimizing the time-frame for the definition of bleeding-related death after acute variceal bleeding in cirrhosis. Eur J Gastroenterol Hepatol 1996 0.75
159 [Systemic hemodynamics in cirrhotic patients: relationship with plasma levels and pulmonary exchange of PGE2]. Ann Ital Med Int 1990 0.75
160 [Semiquantitative angiographic assessment of portal perfusion in cirrhotic patients: relation to hepatic plasma flow]. Gastroenterol Clin Biol 1987 0.75
161 Splenic impedance indices: a useful method to monitor patients after liver transplantation? Hepatology 1998 0.75
162 [Turner's syndrome with aortic insufficiency and intestinal telangiectasis]. Minerva Endocrinol 1985 0.75
163 Relationship between portal blood flow measured by image-directed Doppler ultrasonography and hepatic blood flow measured by indocyanine green constant infusion in patients with cirrhosis. J Clin Ultrasound 1995 0.75
164 Duplex Doppler ultrasonography allows a multiorgan noninvasive approach to splanchnic pharmacodynamics in patients with cirrhosis. Bildgebung 1995 0.75
165 Hemodynamic changes of systemic, hepatic, and splenic circulation following triglycyl-lysin-vasopressin administration in alcoholic cirrhosis. Dig Dis Sci 1988 0.75
166 Lack of correlation between endotoxaemia and renal hypoperfusion in cirrhotics without overt renal failure. Eur J Clin Invest 1982 0.75
167 [Kidney and malignant hypertension. Anatomical and clinical aspects]. Minerva Nefrol 1975 0.75
168 Tubular handling of sodium and phosphate in non-ascitic liver cirrhosis. Scand J Clin Lab Invest 1987 0.75
169 [Liver metabolism of indocyanine green and aminopyrine in liver cirrhosis: relations with functioning liver cell mass]. Minerva Med 1988 0.75
170 Increased renal production of cytochrome P450-dependent metabolites of arachidonic acid in cyclosporine-induced nephrotoxicity. Adv Prostaglandin Thromboxane Leukot Res 1991 0.75
171 The liver: another organ involved in Muir Torre syndrome? Fam Cancer 2012 0.75
172 [Renal blood flow in hepatic cirrhosis determined by the Xe 133 washout method]. Minerva Nefrol 1977 0.75
173 [Pathogenetic relations between distal renal tubular acidosis and sodium metabolism in hepatic cirrhosis]. Minerva Dietol Gastroenterol 1982 0.75
174 [Inhibition of lymphocytic blastogenesis in vitro with asparaginase in normal and leukemic subjects]. Haematologica 1969 0.75
175 Effects of amiloride on renal lithium handling in nonazotemic ascitic cirrhotic patients with avid sodium retention. Hepatology 1992 0.75
176 [Usefulness of urinary enzyme tests in EPH-gestosis]. Minerva Nefrol 1981 0.75
177 Prevention of renal ischemic damage by endothelial protecting agents. Transplant Proc 1995 0.75
178 [Secondary role of a deficiency in chloride reabsorption at the level of Henle's loop in the pathogenesis of Bartter's syndrome]. Minerva Nefrol 1984 0.75
179 [Therapeutic use of ornithine-carbamyl-transferase in liver diseases]. Minerva Dietol Gastroenterol 1982 0.75
180 [Clinical and functional aspects of the kidney in relation to renal and intrarenal hemodynamic changes during hepatic cirrhosis]. Minerva Nefrol 1979 0.75
181 Evaluation of renal tubular damage in liver cirrhosis by urinary enzymes and beta-2-microglobulin excretions. Eur J Clin Invest 1981 0.75
182 [Antihypertensive action and renal effects of guanabenz]. Minerva Cardioangiol 1984 0.75
183 Distal renal tubular acidosis in hepatic cirrhosis: clinical and pathogenetic study. Clin Nephrol 1981 0.75
184 Disagreement between acute and chronic haemodynamic effects of nadolol in cirrhosis: a pathophysiological interpretation. Aliment Pharmacol Ther 2005 0.75
185 [Renal and intrarenal hemodynamics in the course of hepatic cirrhosis before and after porto-systemic shunt]. Minerva Nefrol 1979 0.75
186 [Nutritional therapy in chronic hepatopathy]. Ann Ital Med Int 1997 0.75